These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 2771993)

  • 1. The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ.
    Brosman S
    Prog Clin Biol Res; 1989; 310():193-205. PubMed ID: 2771993
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
    Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
    Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
    [No Abstract]   [Full Text] [Related]  

  • 3. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 4. A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.
    Brosman SA; Lamm DL; van der Meijden AP; Debruyne FM
    Prog Clin Biol Res; 1989; 310():311-23. PubMed ID: 2672019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
    Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM
    Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst).
    Barreto L; Csizer Z; Sparkes JD
    Dev Biol Stand; 1992; 77():229-31. PubMed ID: 1426667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous, oral, or intravesical BCG administration: what is the optimal route?
    Lamm DL; Sarodosy MS; DeHaven JI
    Prog Clin Biol Res; 1989; 310():301-10. PubMed ID: 2672018
    [No Abstract]   [Full Text] [Related]  

  • 9. Bacillus Calmette-Guérin immunotherapy. Techniques and results.
    Brosman SA
    Urol Clin North Am; 1992 Aug; 19(3):557-64. PubMed ID: 1636239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCG for bladder cancer.
    Med Lett Drugs Ther; 1991 Apr; 33(841):29-30. PubMed ID: 2002783
    [No Abstract]   [Full Text] [Related]  

  • 13. BCG vaccine in urinary bladder cancer.
    Brosman SA
    West J Med; 1991 Dec; 155(6):633. PubMed ID: 1812634
    [No Abstract]   [Full Text] [Related]  

  • 14. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group.
    Jakse G; Hall R; Bono A; Höltl W; Carpentier P; de Pauw M; Sylvester R
    Prog Clin Biol Res; 1992; 378():69-74. PubMed ID: 1301588
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravesical BCG therapy in patients with superficial bladder tumors.
    Steg A; Belas M; Leleu C; Boccon-Gibod L
    Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E; Jauhiainen K; Alfthan O
    Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.